These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 3221745)
21. Propafenone: a new antiarrhythmic agent. Chow MS; Lebsack C; Hilleman D Clin Pharm; 1988 Dec; 7(12):869-77. PubMed ID: 3061720 [TBL] [Abstract][Full Text] [Related]
22. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis. Brandi L Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159 [TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics and pharmacodynamics of the acetylcholinesterase inhibitor 2,2,2-trifluoro-1-(3-trimethylsilylphenyl) ethanone in dog. Potential for transdermal patch delivery. Dow J; Dulery BD; Hornsperger JM; Di Francesco GF; Keshary P; Haegele KD Arzneimittelforschung; 1995 Dec; 45(12):1245-52. PubMed ID: 8595078 [TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics of reboxetine enantiomers in the dog. Frigerio E; Benecchi A; Brianceschi G; Pellizzoni C; Poggesi I; Strolin Benedetti M; Dostert P Chirality; 1997; 9(3):303-6. PubMed ID: 9176997 [TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study. Lim KS; Kim JR; Choi YJ; Shin KH; Kim KP; Hong JH; Cho JY; Shin HS; Yu KS; Shin SG; Kwon OH; Hwang DM; Kim JA; Jang IJ Clin Ther; 2008 Oct; 30(10):1817-30. PubMed ID: 19014837 [TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580 [TBL] [Abstract][Full Text] [Related]
27. Stereoselective steady state disposition and action of propafenone in Chinese subjects. Li G; Gong PL; Qiu J; Zeng FD; Klotz U Br J Clin Pharmacol; 1998 Nov; 46(5):441-5. PubMed ID: 9833596 [TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetic and pharmacodynamic interaction between mexiletine and propafenone in human beings. Labbé L; O'Hara G; Lefebvre M; Lessard E; Gilbert M; Adedoyin A; Champagne J; Hamelin B; Turgeon J Clin Pharmacol Ther; 2000 Jul; 68(1):44-57. PubMed ID: 10945315 [TBL] [Abstract][Full Text] [Related]
29. Developmental changes in pharmacokinetics and pharmacodynamics of warfarin enantiomers in Japanese children. Takahashi H; Ishikawa S; Nomoto S; Nishigaki Y; Ando F; Kashima T; Kimura S; Kanamori M; Echizen H Clin Pharmacol Ther; 2000 Nov; 68(5):541-55. PubMed ID: 11103757 [TBL] [Abstract][Full Text] [Related]
30. Comparison of the pharmacodynamic effects of intravenous and oral propafenone. Haefeli EW; Vozeh S; Ha HR; Follath F Clin Pharmacol Ther; 1990 Sep; 48(3):245-54. PubMed ID: 2401123 [TBL] [Abstract][Full Text] [Related]
31. [Effects of propafenone on the parameters of body surface electrocardiogram in comparison with those of disopyramide]. Omori I; Ochiai M; Inoue D; Asayama J; Nakagawa M Kokyu To Junkan; 1993 Jul; 41(7):647-52. PubMed ID: 8337528 [TBL] [Abstract][Full Text] [Related]
32. [Antiarrhythmic efficacy of mexiletine, propafenone and flecainide in ventricular premature beats. A comparative study in patients after myocardial infarction (author's transl)]. Klempt HW; Nayebagha A; Fabry E Z Kardiol; 1982 May; 71(5):340-9. PubMed ID: 6180562 [TBL] [Abstract][Full Text] [Related]
33. Protein binding of indobufen enantiomers: pharmacokinetics of free fraction-studies after single or multiple doses of rac-indobufen. Główka FK; Caldwell J Chirality; 2002 Oct; 14(9):736-41. PubMed ID: 12237835 [TBL] [Abstract][Full Text] [Related]
34. [Determination of oxidative phenotype in a sample population and correlation with the pharmacokinetics of propafenone]. Boriani G; Strocchi E; Capucci A; Boschi S; Frabetti L; Ambrosioni E; Magnani B Cardiologia; 1990 Feb; 35(2):163-9. PubMed ID: 2208201 [TBL] [Abstract][Full Text] [Related]
35. Fluoxetine impairs the CYP2D6-mediated metabolism of propafenone enantiomers in healthy Chinese volunteers. Cai WM; Chen B; Zhou Y; Zhang YD Clin Pharmacol Ther; 1999 Nov; 66(5):516-21. PubMed ID: 10579479 [TBL] [Abstract][Full Text] [Related]
37. An enantiomer-enantiomer interaction of (S)- and (R)-propafenone modifies the effect of racemic drug therapy. Kroemer HK; Fromm MF; Bühl K; Terefe H; Blaschke G; Eichelbaum M Circulation; 1994 May; 89(5):2396-400. PubMed ID: 7910120 [TBL] [Abstract][Full Text] [Related]
38. The influence of CYP2D6 activity on the kinetics of propafenone enantiomers in Chinese subjects. Cai WM; Chen B; Cai MH; Chen Y; Zhang YD Br J Clin Pharmacol; 1999 May; 47(5):553-6. PubMed ID: 10336580 [TBL] [Abstract][Full Text] [Related]
39. Clinical pharmacokinetics of propafenone. Hii JT; Duff HJ; Burgess ED Clin Pharmacokinet; 1991 Jul; 21(1):1-10. PubMed ID: 1914339 [TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetic and pharmacodynamic evaluation of propafenone in patients with ventricular arrhythmia. Propafenone Research Group. Zoble RG; Kirsten EB; Brewington J Clin Pharmacol Ther; 1989 May; 45(5):535-41. PubMed ID: 2721109 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]